Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence
Key Highlights
- ➤HArmonyCa™ launched in UAE, combining hyaluronic acid and calcium hydroxyapatite
- ➤HArmonyCa™ produced visible midface improvement in all eight GLP-1 users at three months
- ➤HArmonyCa™ 24-month randomized study data will be presented at AMWC Dubai
- ➤SKINVIVE™ patient reports showed improved neck appearance and satisfaction
- ➤Middle Eastern patients reported satisfaction with long-term repeated BOTOX® Cosmetic treatment
Expert Statements
Darin Messina, Senior vice president, head of aesthetics research and development, AbbVie
“This meeting brings together the science, clinical expertise and education that continue to shape the aesthetics field in the Middle East and beyond”
Darin Messina, Senior vice president, head of aesthetics research and development, AbbVie
“The breadth of data to be presented at AMWC reflects Allergan Aesthetics' commitment to developing evidence-based portfolio approaches to treatment as the industry continues to evolve alongside patient needs.”
Darin Messina, Senior vice president, head of aesthetics research and development, AbbVie
“We are excited to introduce HArmonyCa™ and its Dual Action Rejuvenating Technology as part of the continued expansion of our aesthetics portfolio.”
Allergan Aesthetics Deepens Science Behind Multimodal Approach at AMWC Dubai, Backed by Growing HArmonyCa™ Evidence PR Newswire
* Allergan Aesthetics will present eight scientific posters featuring new and long-term evidence across HArmonyCa™, JUVÉDERM(®), SKINVIVE™ and BOTOX(®) Cosmetic * The latest HArmonyCa™ data reinforces its dual-action technology, supported by long-term clinical efficacy data and new findings in patients undergoing medical weight loss * The company will also host a series of events and educational activities, including a symposium highlighting its global portfolio approach to treatment with AA Signature™ IRVINE, Calif., Oct. 21, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and a global leader in aesthetics, will showcase the latest scientific evidence and clinical education supporting its expanding global aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) Dubai, taking place October 21-23, 2026.
Get started
Create a free account to read the full story.